Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900969 | 0.79 | HDAC1 (0.64) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL211754 | 0.79 | HDAC1 (0.73) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL1060598 | 0.78 | HDAC1 (0.79) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL210811 | 0.78 | HDAC1 (0.66) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL1064675 | 0.78 | HDAC1 (0.61) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL13390269 | 0.77 | HDAC2 (0.76) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL1689144 | 0.77 | HDAC1 (0.82) | HDAC1HDAC2HDAC3 | |
| SCHEMBL8401704 | 0.77 | HDAC1 (0.89) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL27406949 | 0.76 | HDAC1 (0.69) | HDAC1HDAC2HDAC3MAPK1NCOR2 | |
| SCHEMBL1064065 | 0.76 | HDAC1 (0.60) | HDAC1HDAC2HDAC3MAPK1NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 10/4885HDAC3 4/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 12/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.